Update 2020: Management of Non-Small Cell Lung Cancer

2020/11/11 by Mariam Alexander, So Yeon Kim, Haiying Cheng · 3 citations
Medicine · #Cancer Immunotherapy and Biomarkers #Lung Cancer Diagnosis and Treatment #Lung Cancer Treatments and Mutations

paper · pdf · doi:10.1007/s00408-020-00407-5

crossref issued 2020/11/11 · crossref published 2020/11/11 · crossref published-online 2020/11/11 · openalex publication_date 2020/11/11 · crossref created 2020/11/11 · crossref published-print 2020/12/01 · crossref deposited 2025/04/09 · openalex created_date 2025/10/10 · crossref indexed 2026/08/01 · openalex updated_date 2026/08/01

Citations

• Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
• Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
• Cancer statistics, 2020
• Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial

Cited by

• CIB2 mediates acquired gefitinib resistance by inducing ZEB1 expression and epithelial-mesenchymal transition
• Tissue-specific properties of type 1 dendritic cells in lung cancer: implications for immunotherapy
• Lung cancer [wikipedia]